Neuromodulation to target glucose transporter and/or incretin pathways
AssigneeGeneral Electric Company
InventorsVictoria Eugenia Cotero, Christopher Michael Puleo, John Frederick Graf
Life of this patent
Estimating the term…
Abstract
The subject matter of the present disclosure generally relates to techniques for neuromodulation that include applying energy (e.g., ultrasound energy) into the tissue to cause a change in a glucose transporter pathway molecule and/or an incretin pathway molecule. In one embodiment, the neuromodulation is performed as a treatment of a metabolic disorder.
Claims22
A method for treating a subject having a metabolic disorder, comprising:
- applying ultrasound energy to an internal tissue of the subject having the metabolic disorder to cause a change to a glucose transporter pathway molecule and/or an incretin pathway molecule in the subject to treat the metabolic disorder, wherein the ultrasound energy is applied by an extracorporeal energy application device,
- measuring the change or an indication of the change in the subject;
- and
- determining, based on the measuring, that the ultrasound energy caused the change to the glucose transporter pathway molecule and/or the incretin pathway molecule to treat the subject.
A system for treating a metabolic disorder in a subject, the system comprising:
- an energy application device configured to apply energy to an internal tissue of the subject;
- a controller adapted to control the energy application device to apply the energy to cause a change to a glucose transporter pathway molecule and/or an incretin pathway molecule in the subject;
- and
- an assessment device configured to receive an input indicative of the change.
A method for treating a subject having a metabolic disorder, comprising:
- selecting a region of interest in a liver of the subject;
- applying ultrasound energy to the region of interest of the liver to cause a change to a glucose transporter pathway molecule and/or an incretin pathway molecule in the subject;
- measuring a blood glucose concentration, an excreted glucose concentration, or both, of the subject;
- and
- determining that the ultrasound energy caused the change to the glucose transporter pathway molecule and/or the incretin pathway molecule to treat the subject based on the blood glucose concentration, the excreted glucose concentration, or both.
A method for treating a subject having a metabolic disorder, comprising:
- selecting a region of interest in a gastrointestinal tissue of the subject;
- applying ultrasound energy to the region of interest in the gastrointestinal tissue to cause a change to a glucose transporter pathway molecule and/or an incretin pathway molecule;
- measuring a blood glucose concentration, the blood glucagon-like peptide 1 concentration, or both, of the subject;
- and
- determining that the ultrasound energy caused the change to the glucose transporter pathway molecule and/or the incretin pathway molecule to treat the subject based on the blood glucose concentration, the blood glucagon-like peptide 1 concentration, or both.
Dependencies are inferred from the claim text.